Marone et al. [41] used newly identified ATP-competitive PI3K/mTOR inhibitors to demonstrate that the PI3K and mTOR pathways inhibit tumor growth in a syngeneic B16 mouse melanoma tumor model. The gene discussed is MTOR; the disease is neoplasm.